Stocks and Investing
Stocks and Investing
Mon, November 9, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Graig Suvannavejh Upgraded (ARQT) to Strong Buy and Held Target at $36 on, Nov 9th, 2020
Graig Suvannavejh of Goldman Sachs, Upgraded "Arcutis Biotherapeutics, Inc." (ARQT) to Strong Buy and Held Target at $36 on, Nov 9th, 2020.
Graig has made no other calls on ARQT in the last 4 months.
There is 1 other peer that has a rating on ARQT. Out of the 1 peers that are also analyzing ARQT, 0 agree with Graig's Rating of Hold.
This is the rating of the analyst that currently disagrees with Graig
- Gregg Gilbert of "Truist Securities" Initiated at Strong Buy and Held Target at $38 on, Thursday, October 8th, 2020
Contributing Sources